Immunic Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. Show More...

  • Website https://www.immunic-therapeutics.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.66 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -454.98 -541.9 -2771.2 -141.6 -82.8 -52.4 -52.4 -39.2 -4.52 -0.22
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 1.0 1.0 8.0 10.0
    Book Value Per Share * USD 128.5 77.02 84.32 58.61 13.45 5.63 3.95
    Free Cash Flow Per Share * USD -85.59 -89.2 -47.77 -43.17 -46.42 -4.97
    Return on Assets % -323.6 -68.5 -116.82 -73.48 -52.77 -53.52 -83.72 -110.07 -86.33 -115.4
    Financial Leverage (Average) 1.12 1.11 1.08 1.1 1.21 1.21 1.13 1.13
    Return on Equity % -231.37 -81.77 -57.84 -58.21 -96.01 -132.78 -98.69 -131.37
    Return on Invested Capital % -231.4 -81.8 -57.9 -58.61 -97.2 -134.45 -97.56 -129.76
    Interest Coverage 0.36 -15.23
    Current Ratio 0.44 10.97 9.05 10.2 12.79 11.22 5.65 5.67 4.56 3.73
    Quick Ratio 0.4 10.59 7.88 9.95 12.53 10.95 5.53 5.31 4.15 3.03
    Debt/Equity 0.010 0.010